Plasma Fractionation Market Size, Share, Growth Analysis, By Product (Albumin, Immunoglobulins (Intravenous, Subcutaneous, Others)), By Application (Neurology, Hematology, Oncology, Immunology), By End Use (Hospitals & Clinics, Clinical Research, and Others), By Region - Industry Forecast 2025-2032

Global Plasma Fractionation Market size was valued at around USD 30.87 billion in 2022 and is expected to rise from USD 33.43 billion in 2023 to reach a value of USD 63.27 billion by 2031, at a CAGR of 8.3% over the forecast period (2024–2031).

The plasma fractionation market remains controlled by both historical firms and new entrants which are boosting growth and creativity. Examples of major scion companies are Grifols, CSL Behring, Takeda Pharmaceutical Company, and Octapharma, whose focus is on improving product development and industrial expansion within international borders. These firms invest significantly in research and development to improve processing technologies and product efficacy, positioning themselves strategically to meet the increasing demand for plasma-derived therapies worldwide. 'CSL Behring (Australia) ', 'Grifols (Spain) ', 'Octapharma (Switzerland) ', 'Kedrion (Italy) ', 'China Biologic Products Holdings (China) ', 'Sanquin (Netherlands) ', 'Bio Products Laboratory (UK) ', 'Japan Blood Products Organization (Japan) ', 'LFB Group (France) ', 'Shanghai RAAS Blood Products (China) ', 'Green Cross Corporation (South Korea) ', 'Baxter International Inc. (US) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Beijing Tiantan Biological Products (China) ', 'Biotest AG (Germany) ', 'China National Pharmaceutical Group Co. (Sinopharm) (China) ', 'GC Pharma (South Korea) ', 'ADMA Biologics (US) ', 'Emergent BioSolutions (US) ', 'Renishaw plc (UK) ', 'HP Inc. (USA)'

The rising number of cases relating to diseases related to immunodeficiency disorders and autoimmune conditions stands as an important factor fueling the growth of the global plasma fractionation market. Healthcare professionals use Immunoglobulins for these purposes which causes the demand for these products to spike. This trend stimulates creativity and growth in the development and emergence of plasma-based therapeutic products purification processes and manufacturing. 

There is rising demand for specialized plasma products like immunoglobulins and clotting factor concentrates in the global plasma fractionation market. This is due to the increasing incidence of chronic and autoimmune disorders which requires detailed and effective treatment methods for patients.

Owing to the presence of an advanced healthcare system, extensive research and development activities, and high expenditure on biopharmaceuticals, North America holds the largest global plasma fractionation market share. Health care services and the concept of personalized medicine within these advanced health care systems also contribute to the market for plasma-based medical products, especially immunoglobins and albumin. Moreover, the existence of essential contributors to the market coupled with strong regulatory policies helps in ensuring the safety and effectiveness of the products. The calling burden of chronic diseases is on the rise, and plasma therapies are becoming popular among both practitioners and patients which also serves to enhance the growth of the market in North America, further solidifying its position in the global plasma fractionation market outlook.